Summary
The initial results from the Children's Cancer Study Group (CCSG) study on vindesine are the subject of this report. Vindesine was shown to be active in the treatment of acute lymphocytic leukemia (ALL) in children in a phase-II clinical trial conducted by the CCSG. A phase-III trial is now in progress. The aim of this is to compare the use of vincristine and of vindesine with reference to induction rate, toxicity, and cross-resistance.
This is a preview of subscription content, log in via an institution to check access.
References
Krivit, W.: Minutes of the New Drug Liaison Committee Meeting; February 17th–18th, 1977, pp. 31–73. National Cancer Institute, Division of Cancer Treatment, Cancer Therapy Evaluation Program (1977)
Krivit, W., Hammond, D.: Vindesine: A phase-II study by the Children's Cancer Study Group. Curr. Chemother. 2, 1331–1334 (1978)
Mathé, G., Misset, J., Vassal, F. de, et al.: Phase-II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and Hodgkin's disease: Absence of cross-resistance with vincristine. Cancer Treat. Rep. 62 (5), 805–809 (1978)
Author information
Authors and Affiliations
Additional information
The Children's Cancer Study Group investigators, institutions, and grant numbers are listed in the appendix to this paper
Rights and permissions
About this article
Cite this article
Krivit, W., Chilcote, R., Pyesmany, A. et al. An initial report of a phase-III trial comparing vindesine and vincristine for acute lymphocytic leukemia of childhood. Cancer Chemother. Pharmacol. 2, 267–270 (1979). https://doi.org/10.1007/BF00257193
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00257193